

Synthesis, Reactions and Antitumor Activity of Certain 1,3-diphenylpyrazole-4-carboxaldehyde Derivatives

Atef M. Amer^{1*}, Neveen Ramses² and Sebaey Mahgoub²

¹Department of Chemistry, Faculty of Science, Zagazig University, Egypt.

²Research and Development, Unipharma, El-Obour City, Egypt.

IN continuation of our interest in synthesis of novel heterocycles with anticipated biological activity especially the antitumor activity. In this paper we have discussed synthesis and reaction of 1,3-diphenylpyrazol-4-carboxaldehyde **4** with acetophenone derivatives **1a–d**, active methylene compounds, hydrazines and aniline derivatives to yield the expected derivatives **5a–d**. Also, a series of penta-substituted pyridine derivatives **15a–e** have been synthesized by one-pot three component cyclocondensation reaction of 1,3-diphenylpyrazole-4-carboxaldehyde **1**, malononitrile and thiol derivatives **13a–e** in presence of triethylamine as a catalyst. Also, 2-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(aryl)thiazolidine-4-one **20a–e** has been synthesized from N-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)-aniline derivatives **11a–e** and thioglycolic acid. Some of the synthesized derivatives were screened for their antitumor activity. All the newly synthesized compounds have been characterized by means of elemental analyses, IR, ¹H NMR, ¹³C NMR, MS and in some cases by comparison with the known properties of compound or by comparison with samples prepared by reported unambiguous routes.

Keywords: 1,3-diphenylpyrazol-4-carboxaldehyde, Vilsmeier-Haack reaction, 3,5-Pyridinedicarbonitrile, Antitumor activity.

Introduction

The pyrazole ring is found in numerous pharmaceutically active compounds. This is mainly due to the ease of preparation and the important biological activity. Many pyrazole derivatives have been reported to possess diverse pharmacological activities such as antimicrobial [1–6], anti-inflammatory [7–10], anti-viral [11, 12], antidiabetic [13], analgesic [14] and antiparasitic properties [15].

Pyrazole showed promising anticancer effects [16–22]. In search for better antitumor treatment, a large number of pyrazole derivatives were synthesized and tested over the years, the use of this powerful pharmacophore is very popular and modern [23–25]. On the other hand, pyridine derivatives have occupied a unique position in medicinal chemistry, besides many naturally occurring pyridines. Several synthetic derivatives show interesting biological activities for example, 2-amino-3-cyanopyridines have antibacterial, antimicrobial, antifungal and cardiotoxic activities [26, 27]. In connection with these findings and our interest in the synthesis of fused nitrogen heterocyclic compounds with

expected antitumor activity, we have described the synthesis of 4-substituted pyrazoles utilizing 4-formyl pyrazoles as starting materials.

Experimental

General

All melting points were determined using Electrothermal melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 383 spectrometer (KBr). ¹H NMR spectra were recorded on Bruker AC 200F 300 MHz spectrometer using TMS as an internal reference. ¹³C NMR spectra were measured on a Varian spectrophotometer at 300 MHz, using DMSO-*d*₆ or CDCl₃ as solvent. The Electron Impact mass spectra were obtained at 70 eV using Shimadzu QP-2010 Plus mass spectrometer. The reactions were monitored by thin-layer chromatography (TLC) on silica gel F254 aluminum sheets (Merck), and spots were visualized by UV lamp at 254–365 nm. All cell culture material was obtained from Cambrex Bio Science (Copenhagen, Denmark). All chemicals were from Sigma/ Aldrich, USA, except mentioned. Human breast adenocarcinoma cell line (MCF-7) and human hepatocarcinoma cell line (Hep-G2), were purchased from ATCC, USA

*Corresponding author e-mail: atefamer55@yahoo.com

DOI: 10.21608/EJCHEM.2018.5328.1470

©2017 National Information and Documentation Center (NIDOC)

Chemistry**Synthesis of 1,3-diphenylpyrazole-4-carboxaldehyde 4 [28]**

To (0.01 mole) of acetophenonephenyl hydrazine, (0.01 mole) of Vilsmerier reagent (14.6 mL DMF and 19.10 mL POCl₃) was added dropwise with stirring for one hour. The reaction mixture was refluxed for six hours at 70–80°C, then hydrolyzed on ice/water mixture, and neutralized by 5% NaOH solution till pH 4, the solid formed was filtered, washed with water, dried and crystalized from isopropanol to give compound **4** as yellow white powder in (80%) yield, m.p. = 142–143°C, IR (KBr, cm⁻¹): 3125, 3062 (CH_{ar}), 1673 (C=O), 163, 1599, 1526 (C=N), 1511 (C=C_{aromatic system}); ¹H NMR(CDCl₃): δ (ppm) = 10.09 (s, 1H, CHO), 8.57 s, 1H, H_{pyrazole}), 7.87–7.29 (m, 10H, H_{ar}), 7.53–7.39 (m, 10H, H_{ar}); Anal. Calcd for C₁₆H₁₂N₂O (248.29): C, 77.40; H, 4.87; N, 11.28. Found: C, 77.25; H, 4.72; N, 11.13.

General procedure for synthesis of 1-aryl-3-(1,3-diphenyl-1H-pyrazol-4-yl)prop-2-en-1-one 5a–d [28, 29]

To a solution of 1,3-diphenyl-1H-pyrazol-4-carboxaldehyde **4** (2.48 g, 0.01 mole), aryl methyl ketone **1a–d** (0.01 mole) in ethanol (30 mL), a pellet of KOH was added. The reaction mixture was stirred at room temperature for overnight. The yellow solid precipitated was separated by filtration and recrystallized from (1 : 1) EtOH/DMF mixture to give α-β-unsaturated compounds **5a–d**.

(E)-3-(1,3-Diphenyl-1H-pyrazol-4-yl)-1-phenylprop-2-en-1-one 5a

Yield 82 %; mp 124–126 °C; IR (KBr, cm⁻¹): 1668 (C=O), 1627 (C=N), 1606–1482 (C=C_{ar}); ¹H NMR(CDCl₃): δ (ppm) = 8.57 (s, 1H, H_{pyrazole}), 8.38–7.29 (m, 17H, H_{ar} and CH=CH); ¹³C NMR (CDCl₃): δ (ppm): 190.51 (C=O), 154.26, 139.85, 138.65, 135.78, 133.05, 132.74, 129.97, 129.68, 129.17, 129.12, 128.97, 128.55, 127.66, 127.21, 121.96, 119.79, 118.72 (HC=CH, C=N, C_{ar}); Anal. Calcd for C₂₄H₁₈N₂O (350.42): C, 82.26; H, 5.18; N, 7.99. Found: C, 82.35; H, 5.10; N, 7.80.

(E)-3-(1,3-Diphenyl-1H-pyrazol-4-yl)-1-(p-tolyl)prop-2-en-1-one 5b

Yield 75 %; mp 150–152 °C; IR (KBr, cm⁻¹): 3126, 3056 (CH_{ar}), 1673 (C=O), 1660 (C=N), 1597, 1530, 1510 (C=C_{ar}); Anal. Calcd for C₂₅H₂₀N₂O (364.45): C, 82.39; H, 5.53; N, 7.69. Found: C, 82.50; H, 5.40; N, 7.70.

(E)-1-(4-Chlorophenyl)-3-(1,3-diphenyl-1H-pyrazol-4-yl)prop-2-en-1-one 5c

Yield 85 %; mp 160–162 °C; ¹H NMR(CDCl₃): δ (ppm) = 8.38 (s, 1H, H_{pyrazole}), 7.96–7.29 (m, 16H, H_{ar}); ¹³C NMR (CDCl₃): δ (ppm): 186.01 (C=O), 153.27, 138.74, 138.40, 135.90, 135.20, 131.65, 129.09, 128.92, 128.22, 128.17, 126.67, 126.27, 120.24, 118.75, 117.53 (HC=CH, C=N, C_{ar}); Anal. Calcd for C₂₄H₁₇ClN₂O (384.86): C, 74.90; H, 4.45; N, 7.28. Found: C, 75.00; H, 4.40; N, 7.30.

(E)-1-(4-Bromophenyl)-3-(1,3-diphenyl-1H-pyrazol-4-yl)prop-2-en-1-one 5d

Yield 77 %; mp 180–182 °C; Anal. Calcd for C₂₄H₁₇BrN₂O (429.32): C, 67.14; H, 3.99; N, 6.53. Found: C, 67.25; H, 3.80; N, 6.50.

2-((1,3-Diphenyl-1H-pyrazol-4-yl)methylene)malononitrile 6 [30]

A mixture of malononitrile (0.66, 0.01 mole), 1,3-diphenyl pyrazole-4-carboxaldehyde **4** (2.48 g, 0.01 mole) in ethanol (20 mL) containing few drops of piperidine was refluxed for two hours. After cooling the formed solid was filtered, dried and recrystallized from ethanol to give compound **6** in 85% yield, m.p. 190–191°C, IR (KBr, cm⁻¹): 3068 (CH_{ar}), 2200 (CN), 1590, 1536, 1512 (C=C_{ar}); ¹H NMR (CDCl₃): δ (ppm) = 9.08 (s, 1H, -HC=), 8.57 (s, 1H, H_{pyrazole}), 8.337.87–7.46 (m, 11H, H_{ar}); Anal. Calcd for C₁₉H₁₂N₄ (296.33): C, 77.01; H, 4.08; N, 18.91. Found: C, 76.85; H, 4.16; N, 19.

Ethyl 2-cyano-3-(1,3-diphenyl-1H-pyrazol-4-yl)acrylate 7 [28]

A mixture of 1,3-diphenylpyrazol-4-carboxaldehyde **4** (2.48 g, 0.01 mole), ethyl cyanoacetate (0.135 g, 0.012 mole) in ethanol containing few drops of piperidine were refluxed for 3 hours. The precipitated solid was filtered off and recrystallized from ethanol to give compound **7** as a pale yellow powder, yield 78%, m.p. 200–202°C, IR (KBr, cm⁻¹): 3068 (CH_{ar}), 2200 (CN), 1590, 1536, 1512 (C=C_{ar}); ¹H NMR (CDCl₃): δ (ppm) = 9.17 (s, 1H, -HC=), 8.57 (s, 1H, H_{pyrazole}), 7.88–7.43 (m, 10H, H_{ar}), 4.36 (q, J=7.2, 2H, OCH₂), 1.40 (t, J=7.1, 3H, CH₃); Anal. Calcd for C₂₁H₁₇N₃O₂ (343.39): C, 73.45; H, 4.99; N, 12.24. Found: C, 73.50; H, 5.10; N, 12.12.

(E)-2-cyano-N'-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)acetohydrazide 8 [30]

A mixture of 1,3-diphenylpyrazol-4-carboxaldehyde **4** (2.48 g, 0.01 mole) and cyanoacetic hydrazide (1.00 g, 0.01 mole) in 25 mL ethanol was stirred at room temperature for 5 hours. The precipitate was collected and

recrystallized from ethyl acetate, yield 80%, m.p. 190–192°C. IR (KBr, cm^{-1}): 3225 (NH), 3062 (CH_{ar}), 2980 ($\text{CH}_{\text{aliphatic}}$), 2218 (CN), 1668 (C=O), 1600, 1586, 1512, 1486 (aromatic ring). Anal. Calcd for $\text{C}_{19}\text{H}_{15}\text{N}_5\text{O}$ (329.36): C, 69.29; H, 4.59; N, 21.26. Found: C, 69.15; H, 4.52; N, 21.21.

4-((2-Methylhydrazono)-methyl)-1,3-diphenyl-1H-pyrazole 9

A mixture of 1,3-diphenylpyrazol-4-carboxaldehyde **4** (2.48 g, 0.01 mole) and methyl hydrazine (0.01 mole) in 20 mL methanol containing few drops of acetic acid were refluxed for 3 hours. After cooling the formed solid was filtered, dried and crystallized from methanol to give compound **9**, yield 77%, m.p. 240–242°C. Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{N}_4$ (276.34): C, 73.89; H, 5.84; N, 20.27. Found: C, 73.75; H, 5.80; N, 20.10.

General procedure for synthesis of 4-((2-arylhydrazono)-methyl)-1,3-diphenyl-1H-pyrazole 10 a-e

A mixture of 1,3-diphenylpyrazol-4-carboxaldehyde **4** (2.48 g, 0.01 mole) and aryl hydrazine derivatives (0.01 mole) in 20 mL methanol containing few drops of acetic acid were refluxed for 3 hours. After cooling the formed solid was filtered, dried and recrystallized from methanol to give derivatives **10 a-e**.

1,3-Diphenyl-4-((2-phenylhydrazineylidene)methyl)-1H-pyrazole 10 a [31]

Yield 70%, m.p. 220–222°C. Anal. Calcd for $\text{C}_{22}\text{H}_{18}\text{N}_4$ (338.41): C, 78.08; H, 5.36; N, 16.56. Found: C, 78.1; H, 5.15; N, 16.42.

4-((2-(4-Bromophenyl)hydrazineylidene)methyl)-1,3-diphenyl-1H-pyrazole 10 b

Yield 72%, m.p. 200–202°C. Anal. Calcd for $\text{C}_{22}\text{H}_{17}\text{BrN}_4$ (416.06): C, 63.32; H, 4.11; N, 13.43. Found: C, 63.40; H, 4.20; N, 13.38.

4-((2-(4-Nitrophenyl)hydrazineylidene)methyl)-1,3-diphenyl-1H-pyrazole 10 c

Yield 65%, m.p. 212–214°C. Anal. Calcd for $\text{C}_{22}\text{H}_{17}\text{N}_5\text{O}_2$ (383.41): C, 68.92; H, 4.47; N, 18.27. Found: C, 68.71; H, 4.31; N, 18.15.

4-((2-(2,4-Dinitrophenyl)hydrazineylidene)methyl)-1,3-diphenyl-1H-pyrazole 10 d

Yield 85%, m.p. 271–273°C. Anal. Calcd for $\text{C}_{22}\text{H}_{16}\text{N}_6\text{O}_4$ (428.41): C, 61.68; H, 3.76; N, 19.62. Found: C, 61.62; H, 3.74; N, 19.58.

(E)-1,3-Diphenyl-4-((2-(2,4,6-trichlorophenyl)hydrazineylidene)methyl)-1H-pyrazole 10 e

Yield 65%, m.p. 165–167°C. Anal. Calcd for $\text{C}_{22}\text{H}_{15}\text{Cl}_3\text{N}_4$ (441.74): C, 59.82; H, 3.42; N, 12.68. Found: C, 59.75; H, 3.55; N, 12.60.

General procedure for synthesis of N-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)aniline derivatives 11a-f

A solution of 1,3-diphenylpyrazol-4-carboxaldehyde **4** (2.48 g, 0.01 mole), aniline derivatives (0.01 mole), acetic acid (1 mL) and methanol (30 mL) was refluxed for one hour (some yellow crystals formed under reflux condition). After cooling the reaction mixture was poured into crushed ice, the yellow product was filtered and recrystallized from ethyl acetate to give derivatives **11a-f**.

1-(1,3-Diphenyl-1H-pyrazol-4-yl)-N-phenylmethanimine 11a

Yield 65%, m.p. 150–152°C. Anal. Calcd for $\text{C}_{22}\text{H}_{17}\text{N}_3$ (323.40): C, 81.71; H, 5.30; N, 12.99. Found: C, 81.75; H, 5.22; N, 13.10.

1-(1,3-Diphenyl-1H-pyrazol-4-yl)-N-(p-tolyl)methanimine 11b

Yield 82%, m.p. 150–152°C. IR (KBr, cm^{-1}): 3060 (CH_{ar}), 2913 ($\text{CH}_{\text{aliphatic}}$), 1622 (CH=N), 1595, 1542, 1503, 1450 (Aromatic rings); ^1H NMR (CDCl_3): δ (ppm) = 8.69 (s, 1H, CH=N), 8.56 (s, 1H, $\text{H}_{\text{pyrazole}}$), 7.89–7.11 (m, 14H, Ar-H), 2.39 (s, 3H, CH_3); ^{13}C NMR (CDCl_3): δ (ppm): 154.36, 152.66, 150.16, 139.97, 136.06, 132.75, 130.23, 130.07, 129.96, 129.71, 129.39, 129.27, 129.18, 129.09, 127.83, 127.62, 121.22, 120.81, 119.79 (aromatic carbon and HC=N-), 21.39 (CH_3). Anal. Calcd for $\text{C}_{23}\text{H}_{19}\text{N}_3$ (337.43): C, 81.87; H, 5.68; N, 12.45. Found: C, 81.90; H, 5.57; N, 12.50.

1-(1,3-Diphenyl-1H-pyrazol-4-yl)-N-(4-nitrophenyl)methanimine 11c

Yield 60%, m.p. 142–144°C. Anal. Calcd for $\text{C}_{22}\text{H}_{16}\text{N}_4\text{O}$ (368.40): C, 71.73; H, 4.38; N, 15.21. Found: C, 71.60; H, 4.40; N, 15.00.

N-(4-Bromophenyl)-1-(1,3-diphenyl-1H-pyrazol-4-yl)methanimine 11d

Yield 58%, m.p. 168–170°C. Anal. Calcd for $\text{C}_{22}\text{H}_{16}\text{BrN}_3$ (402.30): C, 65.68; H, 4.01; N, 10.45. Found: C, 65.70; H, 4.15; N, 10.30.

1-(1,3-Diphenyl-1H-pyrazol-4-yl)-N-(3-methoxyphenyl)methanimine 11e

Yield 71%, m.p. 270–272°C. Anal. Calcd for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}$ (353.43): C, 78.16; H, 5.42; N, 11.89. Found: C, 78.20; H, 5.32; N, 11.90.

2-(((1,3-Diphenyl-1H-pyrazol-4-yl)methylene)amino)aniline 11f

Yield 62%, m.p. 280–282°C. Anal. Calcd for C₂₂H₁₈N₄ (338.41): C, 78.08; H, 5.36; N, 16.56. Found: C, 78.10; H, 5.45; N, 16.40.

General procedure for synthesis of 2-amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(arylthio or alkylthio)pyridine-3,5-dicarbonitrile 15a-e

Method A:

A mixture of 1,3-diphenylpyrazole-4-carboxaldehyde **4** (2.48 g, 0.01 mole), malononitrile (1.32 g, 0.02 mole) and thiol derivatives 13a–e (0.01 mole); namely: thiophenol, *o*-aminothiophenol, *p*-aminothiophenol, thioethanol, 2-hydroxythioethanol were refluxed in ethanol (20 mL) containing three drops of triethylamine for 3 hours then the product formed was filtered, dried and recrystallized from ethanol to give **15a-e**

Method B:

A mixture of compound **6** (2.96 g, 0.01 mole), malononitrile (0.66 g, 0.01 mole) and thiol derivatives 13a–e (0.01 mole) were refluxed in ethanol (20 mL) containing three drops of triethylamine for 3 hours, then the product formed was filtered off, dried and recrystallized from ethanol to give 15a-e.

2-Amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile 15a

Yield 57%, m.p. 240–242°C, IR (KBr, cm⁻¹): 3432, 3367, 3311 (NH₂), 3052 (CH_{ar}), 2218 (CN) 1626 (C=N); ¹H NMR(DMSO-d₆): δ (ppm) = 8.28 (s, 1H, Pyrazole), 7.84–7.41 (m, 15H, H_{ar}), 5.41 (br, 2H, NH₂); ¹³C NMR (DMSO-d₆): δ (ppm): 159.61, 152.12, 139.73, 136.18, 132.46, 130.38, 130.21, 129.97, 129.72, 129.59, 129.18, 128.17, 127.92, 127.48, 120.17, 114.25, 8861, 87.00 (C_{ar}, 2CN). Anal. Calcd for C₂₈H₁₈N₆S (470.55): C, 71.47; H, 3.86; N, 17.86. Found: C, 71.50; H, 3.77; N, 17.90.

2-Amino-6-((2-aminophenyl)thio)-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile 15b

Yield 55%, m.p. 250–251°C. IR (KBr, cm⁻¹): 3400–3300 (2NH₂), 3059 (CH_{ar}), 2223 (CN), 1627 (C=N), 1596, 1530, 1503, 1479 (aromatic rings); ¹H NMR(DMSO-d₆): δ (ppm) = 9.17 (s, 1H, NH₂), 8.21 (s, 1H, H_{pyrazole}), 8.06 (d, 1H, J = 8.2, 1H, H_{ar}), 7.87 (d, J = 8.3, 3H, H_{ar}, NH₂), 7.70–7.87 (m, 2H, H_{ar}), 3.43–7.60 (m, 13H, H_{ar}); ¹³C NMR (DMSO-d₆): δ (ppm): 162.95, 156.14 ,

154.11, 139.48, 138.54, 135.06, 131.70, 130.07, 129.62, 129.43, 128.75, 128.35, 127.21, 126.21, 123.93, 121.91, 120.30, 117.59, 115.96, 103.94 (C_{ar}, 2CN). Anal. Calcd for C₂₈H₁₉N₇S (485.57): C, 69.26; H, 3.94; N, 20.19. Found: C, 69.30; H, 4.00; N, 20.25.

2-Amino-6-((4-aminophenyl)thio)-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile 15c

Yield 60%, m.p. 260–262°C, IR (KBr, cm⁻¹): 3470, 3337, 3233 (2NH₂), 2212 (CN), 1626 (C=N); ¹H NMR(DMSO-d₆): δ (ppm) = 7.97 (s, 1H, H_{pyrazole}), 7.95 (d, J = 7.8Hz, 2H, H_{ar}), 7.74 (br, 2H, NH₂), 7.18 (d, J = 8.7Hz, 2H, H_{ar}), 6.62 (d, J = 8.7Hz, 2H, H_{ar}), 5.59 (s, 2H, NH₂). Anal. Calcd for C₂₈H₁₉N₇S (485.57): C, 69.26; H, 3.94; N, 20.19. Found: C, 69.29; H, 4.00; N, 20.25.

2-Amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(ethylthio)pyridine-3,5-dicarbonitrile 15d

Yield 62%, m.p. 250–252°C. IR (KBr, cm⁻¹): 3446, 3361, 3176 (NH₂), 2214 (CN), 1632 (C=N); ¹H NMR(CDCl₃): δ (ppm) = 8.25 (s, 1H, H_{pyrazole}), 7.81 (d, J = 7.8Hz, 2H, H_{ar}), 7.52 (s, 4H, H_{ar}), 7.40 (s, 4H, H_{ar}), 5.60 (s, 2H, NH₂), 3.22 (q, J = 7.3 Hz, 2H, CH₂), 1.41 (t, J = 7.3Hz, 3H, CH₃); ¹³C NMR (CDCl₃): δ (ppm): 169.87, 159.69, 152.03, 150.39, 139.72, 132.52, 130.00, 129.18, 128.13, 127.91, 120.10, 115.51, 115.24, 114.39, 97.63, 87.51 (Car, 2CN), 25.54(CH₂), 14.45 (CH₃). Anal. Calcd for C₂₄H₁₈N₆S (422.51): C, 68.23; H, 4.29; N, 19.89. Found: C, 68.12; H, 4.23; N, 19.81.

2-Amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-((2-hydroxyethyl)thio)pyridine-3,5-dicarbonitrile 15e

Yield 48%, m.p. 200–203°C. Anal. Calcd for C₂₄H₁₈N₆OS (438.51): C, 65.74; H, 4.14; N, 19.17. Found: C, 65.69; H, 4.12; N, 19.12.

Synthesis of 2-amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-hydroxypyridine-3,5-dicarbonitrile 16.

2-Amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(phenylthio)-pyridine-3,5-dicarbonitrile **15a** (0.47 g, 0.001 mole) was refluxed in ethanolic NaOH 30% (10 mL) at 120°C with stirring for 5 hours, the reaction was then cooled, the solid separated was filtered off, dried and recrystallized from acetic acid to give compound **16** as colorless crystals in 70% yield, m.p.: 236°C. IR (KBr, cm⁻¹): 3489, 3440, 3367, 3168(NH₂, OH), 2226 (CN), 1636 (C=N). Anal. Calcd for C₂₂H₁₄N₆O (378.40): C, 69.83; H, 3.73; N, 22.21. Found: C, 69.81; H, 3.68; N, 22.15.

Synthesis of 3,6-diamino-4-(1,3-diphenylpyrazol-4-yl)pyrazolo[3,4-b]pyridine-5-carbonitrile 17.

A solution of 2-amino-4-(1,3-diphenyl-1*H*-pyrazol-4-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile **15a** (4.70 g, 0.01 mole) or 2-amino-6-chloro-4-(1,3-diphenyl-1*H*-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **18** (47.70 g, 0.01 mole) with hydrazine hydrate (1.00 g, 0.02 mole) were refluxed in presence of *n*-butanol at 120°C for 30 min. The yellow solid formed on hot was collected by filtration, washed with alcohol and recrystallized from ethanol to give 3,6-diamino-4-(1,3-diphenylpyrazol-4-yl)pyrazolo[3,4-*b*]pyridine-5-carbonitrile **17** in 65% yield, m.p. 280°C. IR (KBr, cm⁻¹): 3468, 3382, 3362, 3185 (NH, NH₂), 2220 (CN), 1632 (C=N), 1598, 1508, 1492 (aromatic rings); ¹H NMR(DMSO-*d*₆): δ (ppm) = 8.56 (s, 1H, H_{pyrazole}), 7.81 (d, *J* = 8.4 Hz, 2H, H_{ar}), 7.48–7.60 (m, 8H, H_{ar}), 6.83 (s, 2H, NH₂, pyridine), 4.36 (s, 2H, NH₂, pyrazole). Anal. Calcd for C₂₂H₁₆N₈ (392.43): C, 67.34; H, 4.11; N, 28.55. Found: C, 67.40; H, 4.21; N, 28.37.

Synthesis of 2-amino-6-chloro-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile 18

A mixture of 2-amino-6-hydroxy-4-(1,3-diphenyl-1*H*-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **16** (3.92 g, 0.01 mole), PCl₅ (2.0 g) and POCl₃ (10 mL) was heated on water bath for 7 hours, the resulting solution was added dropwise onto crushed ice. The solid product obtained was filtered off, washed several times with water, dried and recrystallized from ethanol to give 2-amino-6-chloro-4-(1,3-diphenyl-1*H*-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **18** in 62% yield, m.p. > 300°C.

Anal. Calcd for C₂₂H₁₃ClN₆ (396.84): C, 66.59; H, 3.30; N, 21.18. Found: C, 66.52; H, 3.28; N, 21.12.

*Synthesis of 3,6-diamino-1-methyl-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyrazolo[3,4-*b*]pyridine-5-carbonitrile 19.*

A mixture of 2-amino-4-(1,3-diphenyl-1*H*-pyrazol-4-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile **15a** (4.70 g, 0.01 mole) or 2-amino-6-chloro-4-(1,3-diphenyl-1*H*-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **18** (4.70 g, 0.01 mole) and methyl hydrazine (10 mL) was heated with stirring under reflux at 150°C for 3 hours the orange yellow solid formed was separated by filtration, washed with alcohol and recrystallized from ethyl acetate or acetic acid to give the expected product **19** in 75% yield m.p. 300°C.

Anal. Calcd for C₂₃H₁₈N₈ (406.45): C, 67.97; H, 4.46; N, 27.57. Found: C, 68.00; H, 4.42; N, 27.50.

Synthesis of 3-aryl-2-(1,3-diphenyl-1H-pyrazol-4-yl)thiazolidine-4-one 20a-e [32]

A mixture of 1,3-diphenyl-4-(aryliminomethylene)pyrazole (0.01 mole) and mercaptoacetic acid (1.10 g, 0.012 mole) in dry benzene (80 mL) was refluxed for 15 hours using Dean-Stark separator (to separate the aqueous benzene layer from time to time). Then, evaporate all the solvent, washed the oil residue with petroleum ether 40-60 or ether and recrystallize the yellow solid from methylene chloride or ethyl acetate to give derivatives **20a-e**.

2-(1,3-Diphenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one 20a

Yield 50%, m.p. 177–179°C; ¹H NMR(CDCl₃): δ (ppm) = 8.02 (s, 1H, H_{pyrazole}), 7.07–7.70 (m, 15H, H_{ar}), 6.38 (s, 1H, CH), 3.91 (d, *J* = 1.3 Hz, 2H, CH₂); ¹³C NMR (CDCl₃): δ (ppm): 170.87 (C=O), 152.15, 139.92, 137.67, 132.57, 129.65, 129.51, 129.10, 128.95, 128.86, 127.44, 127.40, 127.34, 125.62, 120.99, 119.49 (aromatic carbons), 57.47 (CH), 33.93 (CH₂). Anal. Calcd for C₂₄H₁₉N₃OS (397.50): C, 72.52; H, 4.82; N, 10.57. Found: C, 72.48; H, 4.78; N, 10.47.

*2-(1,3-Diphenyl-1H-pyrazol-4-yl)-3-(*p*-tolyl)thiazolidin-4-one 20b*

Yield 50%, m.p. 183–185°C. ¹H NMR(CDCl₃): δ (ppm) = 8.10 (s, 1H, H_{pyrazole}), 6.90–7.83 (m, 14H, H_{ar}), 6.40 (s, 1H, CH), 3.6 (d, *J* = 1.3 Hz, 2H, CH₂), 2.33 (s, 3H, CH₃). Anal. Calcd for C₂₅H₂₁N₃OS (411.52): C, 72.97; H, 5.14; N, 10.21. Found: C, 72.80; H, 5.20; N, 10.10.

2-(1,3-Diphenyl-1H-pyrazol-4-yl)-3-(4-nitrophenyl)thiazolidin-4-one 20c

Yield 35%, m.p. 175–177°C. MS (*m/z*): 444 [M⁺+2, 24%], 443 [M⁺+1, 37%], 442 [M⁺, 37%], 61 [base peak, 100%]. Anal. Calcd for C₂₄H₁₈N₄O₃S (442.49): C, 65.15; H, 4.10; N, 12.66. Found: C, 65.20; H, 4.00; N, 12.70.

3-(4-Bromophenyl)-2-(1,3-diphenyl-1H-pyrazol-4-yl)thiazolidin-4-one 20d

Yield 35%, m.p. 165–167°C. IR (KBr, cm⁻¹): 3050 (CH_{ar}), 2921 (CH_{aliphatic}), 1710 (C=O), 1651 (C=N), 1617, 1594, 1537, 1484 (Aromatic rings); ¹H NMR(CDCl₃): δ (ppm) = 8.08 (s, 1H, H_{pyrazole}), 7.10–7.70 (m, 14H, H_{ar}), 6.41 (s, 1H, CH), 3.88 (d, *J* = 1.3 Hz, 2H, CH₂). Anal. Calcd for C₂₄H₁₈BrN₃OS (476.39): C,

60.51; H, 3.81; N, 8.82. Found: C, 60.38; H, 4.00; N, 8.70.

2-(1,3-Diphenyl-1H-pyrazol-4-yl)-3-(4-methoxyphenyl)thiazolidin-4-one 20e

Yield 38%, m.p. 187–189°C. Anal. Calcd for $C_{25}H_{21}N_3O_2S$ (427.52): C, 70.24; H, 4.95; N, 9.83. Found: C, 70.21; H, 4.86; N, 9.79.

Antitumor activity

Human breast adenocarcinoma cell line (MCF-7) and human hepatocarcinoma cell line (Hep-G2) were used to evaluate the cytotoxic effect of the tested drugs. Cells were routinely cultured in DMEM (Dulbecco's Modified Eagle's Medium), which was supplemented with 10% fetal bovine serum (FBS), 2 mL-glutamine, containing 100 units/mL penicillin G sodium, 100 units/mL streptomycin sulphate, and 250 ng/mL amphotericin B. Cells were maintained at sub-confluency at 37°C in humidified air containing 5% CO_2 . For sub-culturing, monolayer cells were harvested after trypsin/EDTA treatment at 37°C. Cells were used when confluence had reached 75%. Tested drugs were dissolved in dimethyl sulphoxide (DMSO), and then diluted thousand times in the assay. Cytotoxicity of tested drugs was measured against MCF-7 and Hep-G2 cells using the MTT Cell Viability Assay. MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) assay is based on the ability of active mitochondrial dehydrogenase enzyme of living cells to cleave the tetrazolium rings of the yellow MTT and form a dark blue insoluble formazan crystals which are largely impermeable to cell membranes, resulting in its accumulation within healthy cells. Solubilization of the cells results in the liberation of crystals, which are then solubilized. The number of viable cells is directly proportional to the level of soluble formazan dark blue color. The extent of the reduction of MTT was quantified by measuring


the absorbance at 570 nm [33]. MTT solution was prepared at concentration of 5mg/mL in 0.9%NaCl and acidified isopropanol was prepared by dissolving 0.04 N HCl in absolute isopropanol. Cells (0.5×10^5 cells/ well), in serum-free media, were plated in a flat bottom 96-well microplate, and treated with 20 μ L of different concentrations of the tested drugs for 48 h at 37° C, in a humidified 5% CO_2 atmosphere. After incubation, media were removed and 40 μ L MTT solution / well were added and incubated for an additional 4 h. MTT crystals were solubilized by adding 180 μ L of acidified isopropanol/well and plate was shaken at room temperature, followed by photometric determination of the absorbance at 570 nm using microplate ELISA reader. Triplicate repeats were performed for each concentration and the average was calculated. Data were expressed as the percentage of relative viability compared with the untreated cells compared with the vehicle control, with cytotoxicity indicated by <100% relative viability. Percentage of relative viability was calculated using the following equation:

$$\left[\frac{\text{Absorbance of treated cells}}{\text{Absorbance of control cells}} \right] \times 100$$


Then the half maximal inhibitory concentration (IC_{50}) was calculated from the equation of the dose response curve.

Results and Discussion

1,3-diphenylpyrazole-4-carboxaldehyde **4** was prepared by reaction of acetophenone **1** with phenyl hydrazine **2** and sodium acetate in ethanol; subsequent reaction of benzyl hydrazone **3** under Vilsmeier-Haack conditions afforded 1,3-diphenylpyrazole-4-carboxaldehyde **4**. The structure of 1,3-diphenylpyrazole-4-carboxaldehyde **4** was confirmed through comparison of its physical data with reported data [28, 29].




A proposed mechanism for the formation of compound **4** is outlined in the following scheme [36]



Proposed mechanism for the formation of 4-formylpyrazoles 4

The Claisen-Schmidt condensation of 1,3-diphenyl-pyrazole-4-carboxaldehyde 4 with

acetophenone derivatives 1a-d afforded the corresponding pyrazolicchalcones 5a-d.




Scheme 2.

The structure of α,β -unsaturated compounds **5a-d** were established on the basis of their elemental analysis, spectral data, and comparison of its physical data with reported data [37]. The IR spectrum showed absorption bands at 1668–1627 cm^{-1} due to carbonyl group, C=N group and 1606–1482 cm^{-1} due to aromatic ring. ^1H NMR spectrum of **5a** in CDCl_3 showed signals at 7.29–8.38 (m, 17H, H_{ar} , CH=CH), 8.57 (s, 1H, $\text{H}_{\text{pyrazole}}$). The IR spectrum of **5b** showed absorption bands at 3126, 3056 cm^{-1} due to CH aromatic, 1673 cm^{-1} due to carbonyl group, 1660 cm^{-1} due to C=N group, 1597, 1530, 1510 cm^{-1} due to aromatic ring. The ^1H NMR spectrum of **5c** in CDCl_3 showed signals at 7.29–7.96 (m, 16H, H_{ar}), 8.38 (s, 1H, $\text{H}_{\text{pyrazole}}$).

The condensation reaction of 1,3-diphenylpyrazole-4-carboxaldehyde **4** with active methylene compounds namely:


malononitrile, ethyl cyanoacetate, and cyanoacetic acid hydrazide afforded the expected compounds **6–8** respectively as shown in Scheme 3. While treatment of **4** with hydrazines namely: methyl hydrazine, phenyl hydrazine, p-bromophenylhydrazines, p-nitrophenyl hydrazine, o,p-dinitrophenyl hydrazine, 2,4,6-trichlorophenyl hydrazine afforded the expected hydrazones **9,10a-e** respectively. Also, the condensation reaction of 1,3-diphenylpyrazol-4-carboxaldehyde **4** with aniline derivatives namely; aniline, p-methylaniline, p-nitroaniline, p-bromoaniline, m-methoxyaniline, o-phenylenediamine, 4-nitro-m-phenylenediamine, in refluxing methanol containing traces of acetic acid afforded the expected base compounds **11a-g** respectively as shown in Scheme 3.



Scheme 3

In the ^1H NMR spectra of these Schiff bases, the pyrazole H-5 and the azomethine proton resonate as singlets at 8.56 and 8.69 respectively. The structure of compounds **6**, **11a-g** were confirmed by elemental analysis and spectral data. The IR spectrum of 2-(1,3-diphenyl-1H-pyrazol-4-yl)methylene) malononitrile **6** showed absorption bands at 3068 cm^{-1} due to CH aromatic, 2200 cm^{-1} due to cyano group and $1590, 1536, 1512\text{ cm}^{-1}$ due to aromatic rings. The ^1H NMR spectrum of **6** in CDCl_3 showed signals at δ 7.46–7.87 (m, 11H, H_{ar}) and 9.08 (s, 1H, $-\text{CH}=\text{C}$) ppm. The ^1H NMR spectrum of **7** in CDCl_3 showed signals at 1.40 (t, $J=7.1$, 3H, CH_3), 4.36 (q, $J=7.1$, 2H, OCH_3), 7.43–7.88 (m, 10H, H_{ar}), 8.33 (s, 1H, $\text{H}_{\text{pyrazole}}$) 9.17 (s, 1H, $-\text{HC}=\text{C}$) ppm. The IR spectrum of (E)-2-cyano- N' (1,3-diphenyl-1H-pyrazol-4-yl)methylene) acetohydrazide **8** showed absorption bands at


3225 cm^{-1} due to NH group, 3062 cm^{-1} due to CH aromatic, 2980 cm^{-1} due to CH aliphatic, 2218 cm^{-1} due to cyano group, 1668 cm^{-1} due to carbonyl group and $1600, 1586, 1512, 1486\text{ cm}^{-1}$ due to aromatic rings. The IR spectrum of **11b** showed absorption bands at 3060 cm^{-1} due to CH aromatic, 2913 cm^{-1} due to CH aliphatic, 1622 due to $\text{C}=\text{N}$ group and $1595, 1542, 1503, 1450\text{ cm}^{-1}$ due to aromatic rings. The ^1H NMR spectrum of **11b** in CDCl_3 showed signals at 2.39 (s, 3H, CH_3), 7.11–7.89 (m, 14H, H_{ar}), 8.56 (s, 1H, $\text{H}_{\text{pyrazole}}$) and 8.69 (s, 1H, $\text{HC}=\text{N}-$) ppm. It has been reported [38] that the condensation of benzylidenemalononitrile with benzenethiol and malononitrile was carried out in ethanol containing triethylamine at reflux temperature afforded 2-amino-4-phenyl-3,5-dicyano-6-thiophenylpyridine **12** [39].



Scheme 4

A series of pentasubstituted pyridine derivatives **15a-e** has been synthesized by one-pot three component cyclocondensation reaction of 1,3-diphenylpyrazole-4-carboxaldehyde **4**, malononitrile and thiol **13a-e** in the presence of triethylamine as catalyst (method A). The previous mixture in refluxing ethanol gives moderate to

good yield 35–69% in a short experimental time (Scheme 5). On the other hand, 2-(1,3-diphenyl-1H-pyrazol-4-yl)-methylene)malononitrile **6**, malononitrile and thiol **13a-e** was carried out in ethanol containing triethylamine to yield **15a-e** (method B) as shown in Scheme 5.



Reagents and conditions:

(i) Et_3N , EtOH , reflux 90 min


(ii) $\text{CH}_2(\text{CN})_2$, **15a**, $\text{R}=\text{Ph}$, **b**, $\text{R}=\text{o}-(\text{NH}_2)\text{Ph}$, **c**, $\text{R}=\text{p}-(\text{NH}_2)\text{Ph}$, **d**, $\text{R}=\text{CH}_2\text{CH}_3$, **e**, $\text{R}=\text{CH}_2\text{CH}_2\text{OH}$

Scheme 5.

The structures of all the new synthesized compounds were established by ^1H NMR and elemental analysis. The IR spectra of **15a** showed absorption bands at 3432, 3367 and 3311 cm^{-1} for amino group, 3052 cm^{-1} due to CH aromatic, 2218 cm^{-1} due to cyano group and 1626 cm^{-1} due to C=N bonds. The ^1H NMR spectrum of 2-amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile **15a** in CDCl_3 exhibited bands at δ 5.41 (br, 2H, NH_2), 7.41–7.84 (m, 15H, H_{ar}), 8.28 (s, 1H, $\text{H}_{\text{pyrazole}}$) ppm. The IR spectrum of 2-amino-6-(2-amino-phenylthio)-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **15b** showed absorption bands at 3400–3300 cm^{-1} (broad) due to two amino groups, 3059 cm^{-1} due to CH aromatic 2223 cm^{-1} due to cyano group, 1627 cm^{-1} due to C=N group, and 1596, 1530, 1503, 1479 cm^{-1} due to aromatic rings. The ^1H NMR spectrum of compound **15b** in DMSO-d_6 exhibited bands at 3.43–7.60 (m, 13H, H_{ar}), 7.70–7.87 (m, 2H, H_{ar}), 7.87 (d, $J=8.3, 3\text{H}$, $\text{H}_{\text{ar}} + \text{NH}_2$), 8.06 (d, 1H, $J=8.2$, 1H, H_{ar}), 8.21 (s, 1H, $\text{H}_{\text{pyrazole}}$), 9.17 (s, 1H, NH_2) ppm. The ^1H NMR spectrum of 2-amino-6-(4-aminophenylthio)-

4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **15c** in DMSO-d_6 showed bands at δ 5.59 (s, 2H, NH_2), 6.62 (d, $J=8.7\text{Hz}$, 2H, H_{ar}), 7.18 (d, $J=8.7\text{Hz}$, 2H, H_{ar}), 7.74 (br, 2H, NH_2), 7.95 (d, $J=7.8\text{Hz}$, 2H, H_{ar}), 7.97 (s, 1H, $\text{H}_{\text{pyrazole}}$) ppm. The IR spectrum of **15c** showed absorption bands at 3470, 3337, 3233 cm^{-1} due to amino groups, 2212 cm^{-1} due to cyano groups and 1626 cm^{-1} due to C=N group. The ^1H NMR spectrum of 2-amino-6-ethylthio-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **15d** in CDCl_3 showed bands at δ 1.41 (t, $J=7.3\text{Hz}$, 3H, CH) 3.22 (q, $J=7.3\text{Hz}$, 2H, CH_2), 5.60 (s, 2H, NH_2), 7.40 (s, 4H, H_{ar}), 7.52 (s, 4H, H_{ar}), 7.81 (d, $J=7.8\text{Hz}$, 2H, H_{ar}), 8.25 (s, 1H, $\text{H}_{\text{pyrazole}}$) ppm. The IR spectrum of **15d** showed absorption bands at 3446, 3361, 3176 cm^{-1} due to NH_2 group, 2214 cm^{-1} due to two cyano groups, 1632 cm^{-1} due to C=N groups.

Hydrolysis of 2-amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile **15a** with NaOH (30%) under reflux condition for two hours afforded 2-amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-hydroxypyridine-3,5-dicarbonitrile **16**.



Scheme 6.

The structure of compound **16** was confirmed by elemental analysis and spectral data. The IR spectrum of compound **16** showed absorption bands at 3489, 3440, 3367, 3168 cm^{-1} due to NH_2 and OH groups, 2222 cm^{-1} due to cyano groups and 1636 cm^{-1} due to C=N group.


Synthesis of 3,6-diamino-4-(1,3-diphenylpyrazol-4-yl)pyrazolo[3,4-b]pyridine-5-carbonitrile **17** in good yield was reported via the fusion of 2-amino-4-(1,3-diphenyl-1H-pyrazol-4-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile **15a** or 2-amino-6-(2-amino-

phenylthio)-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **15b** with hydrazine hydrate. On the other hand, reaction of 2-amino-6-chloro-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine-3,5-dicarbonitrile **18** with hydrazine hydrate in n-butanol at reflux temperature gave the same compound **17**. Similarly, treatment of compounds **15a** or **15b** with methyl hydrazine gave 3,6-diamino-1-methyl-4-(1,3-diphenyl-1H-pyrazol-4-yl)pyrazolo[3,4-b]pyridine-5-carbonitrile **19** as shown in Scheme 7.

The chemical structure of compounds **17** and **19** was confirmed by elemental analysis and spectral data. The IR spectrum of **17** showed absorption bands at 3468, 3382, 3362, 3185 cm^{-1} characteristic for NH and NH_2 groups, 2220 cm^{-1} due to cyano group, 1632 cm^{-1} due to C=N group, 1598, 1508, 1492 cm^{-1} due to aromatic rings. The ^1H NMR spectrum of **17** in DMSO- d_6 showed signals at δ . 4.36 (s, 2H, $\text{NH}_{2\text{pyrazole}}$), 6.83 (s, 2H,

$\text{NH}_{2\text{pyridine}}$), 7.48–7.60 (m, 8H, H_{ar}), 7.81 (d, $J=8.4\text{Hz}$, 2H, H_{ar}), 8.56 (s, 1H, $\text{H}_{\text{pyrazole}}$) ppm.

The reaction of N-((1,3-diphenyl-1H-pyrazol-4-yl) methylene-aniline derivatives **11a-e** with thioglycolic acid in non-polar solvent at reflux temperature gave 2-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(aryl)-thiazolidin-4-one **20a-e** in low yield 20–38%.



Scheme 8.

Structure of all the synthesized compounds, were established by element analysis and spectral data. The IR spectra of **20d** showed absorption bands at 3050 cm^{-1} due to CH aromatic, 2921 cm^{-1} due to CH aliphatic, 1710 cm^{-1} due to carbonyl group, 1651 cm^{-1} due to C=N group, 1617, 1594, 1537, 1484 cm^{-1} due to aromatic rings. The $^1\text{HNMR}$ of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-3-phenylthiazolidin-4-one **20a** in CDCl_3 exhibited signals at δ 53.91 (d, $J=1.3\text{Hz}$, 2H, CH_2), 6.38 (s, 1H, CH) 7.07–7.70 (m, 15H, H_{ar}), 8.02 (s, 1H, $\text{H}_{\text{pyrazole}}$). The $^1\text{HNMR}$ spectrum of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-3-p-tolylthiazolidin-4-one **20b** in CDCl_3 exhibited signals at δ 2.33 (s, 3H, CH_3), 3.6 (d, $J=1.3\text{ Hz}$, 2H, CH_2), 6.40 (s, 1H, CH), 6.90–7.83 (m, 14H, H_{ar}), 8.10 (s, 1H, $\text{H}_{\text{pyrazole}}$) ppm. The mass spectrum of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(4-nitrophenyl)thiazolidin-4-one **20c** showed molecular ion peak at m/e 444 [M^{+2} , 24%], 443 [M^{+1} , 37%], 442 [M^{+} , 37%] and base

peak at 61 [100%]. The ^1H NMR spectrum of 3-(4-bromophenyl)-2-(1,3-diphenyl-1H-pyrazol-4-yl)-thiazolidin-4-one **20d** in CDCl_3 showed signals at δ 3.88 (d, $J=1.3\text{Hz}$, 2H, CH_2), 6.41 (s, 1H, CH), 7.10–7.70 (m, 14H, H_{ar}), 8.08 (s, 1H, $\text{H}_{\text{pyrazole}}$) ppm.

Antitumor activity

Some of the new prepared compounds were screened for antitumor activity. Using MTT assay, the effect of each compound on the proliferation of MCF-7 and Hep-G2 cells were studied after 48 h of incubation. As shown in the figures, the treatment of MCF-7 cells as well as Hep-G2 with some drugs does not show any valuable cytotoxic effect against MCF-7 or HepG2 as shown in Fig. 1 and 2 respectively concluded from their IC_{50} values $>1000\ \mu\text{g/mL}$ while the treatment with the other drugs showed increase in the proliferation of the cells.

TABLE 1. Drugs that show some sort of cytotoxicity

S/N	Drug	Calculated $\text{IC}_{50}\ \mu\text{g/mL}$
1	5b	638.655
2	10c	452.5519
3	10d	4426.147
4	15a	1464.463
5	15b	8025.00
6	20a	926.7225




Fig. 1. Cytotoxic effect of the samples against MCF-7 cells using MTT assay (n=4), data expressed as mean value of cell viability (% of control) \pm S.D.




Fig. 2. Cytotoxic effect of the samples against Hep-G2 cells using MTT assay (n=4), data expressed as mean value of cell viability (% of control) \pm S.D.

References

1. Bazgir, A., Khanaposhtani, M.M., Soorki, A.A., One-pot synthesis and antibacterial activities of pyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidine-dione derivatives., *Bioorg. Med. Chem. Lett.*, **18**, 5800–5803 (2008).
2. Gilbert, A.M., Failli, A., Shumsky, J., Yang, Y., Severin, A., Singh, G., Hu, W., Keeney, D., Petersen, P.J., Katz, A.H., Pyrazolidine-3,5-diones and 5-Hydroxy-1 H -pyrazol-3(2 H)-ones, Inhibitors of UDP- N -acetylenolpyruvyl Glucosamine Reductase., *J. Med. Chem.*, **49**, 6027–6036 (2006).
3. Liu, X.-H., Cui, P., Song, B.-A., Bhadury, P.S., Zhu, H.-L., Wang, S.-F., Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives., *Bioorg. Med. Chem.*, **16**, 4075–4082 (2008).
4. Prakash, O., Kumar, R., Parkash, V., Synthesis and antifungal activity of some new 3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl) chromones., *Eur. J. Med. Chem.*, **43**, 435–440 (2008).
5. Sullivan, T.J., Truglio, J.J., Boyne, M.E., Novichenok, P., Zhang, X., Stratton, C.F., Li, H.-J., Kaur, T., Amin, A., Johnson, F., Slayden, R.A., Kisker, C., Tonge, P.J., High Affinity InhA Inhibitors with Activity against Drug-Resistant Strains of Mycobacterium tuberculosis., *ACS Chem. Biol.*, **1**, 43–53 (2006).
6. Sharma, P.K., Kumar, S., Kumar, P., Kaushik, P., Kaushik, D., Dhingra, Y., Aneja, K.R., Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory–antimicrobial agents., *Eur. J. Med. Chem.*, **45**, 2650–2655 (2010).
7. Tewari, A.K., Srivastava, P., Singh, V.P., Singh, A., Goel, R.K., Mohan, C.G., Novel anti-inflammatory agents based on pyrazole based dimeric compounds; design, synthesis, docking and in vivo activity., *Chem. Pharm. Bull. (Tokyo)*, **58**, 634–8 (2010).
8. Szabó, G., Fischer, J., Kis-Varga, Á., Gyires, K., New Celecoxib Derivatives as Anti-Inflammatory Agents., *J. Med. Chem.*, **51**, 142–147 (2008).
9. Benaamane, N., Nedjar-Kolli, B., Bentarzi, Y., Hammal, L., Geronikaki, A., Eleftheriou, P., Lagunin, A., Synthesis and in silico biological activity evaluation of new N-substituted pyrazolo-oxazin-2-one systems., *Bioorg. Med. Chem.*, **16**, 3059–3066, (2008).
10. Rosati, O., Curini, M., Marcotullio, M.C., Macchiarulo, A., Perfumi, M., Mattioli, L., Rismondo, F., Cravotto, G., Synthesis, docking studies and anti-inflammatory activity of 4,5,6,7-tetrahydro-2H-indazole derivatives., *Bioorg. Med. Chem.*, **15**, 3463–3473 (2007).
11. El-Sabbagh, O.I., Baraka, M.M., Ibrahim, S.M., Pannecouque, C., Andrei, G., Snoeck, R., Balzarini, J., Rashad, A.A., Synthesis and antiviral activity of new pyrazole and thiazole derivatives., *Eur. J. Med. Chem.*, **44**, 3746–3753 (2009).
12. Ouyang, G., Chen, Z., Cai, X.-J., Song, B.-A., Bhadury, P.S., Yang, S., Jin, L.-H., Xue, W., Hu, D.-Y., Zeng, S., Synthesis and antiviral activity of novel pyrazole derivatives containing oxime esters group., *Bioorg. Med. Chem.*, **16**, 9699–9707 (2008).
13. Soliman, R., Mokhtar, H., Mohamed, H.F., Synthesis and Antidiabetic Activity of Some Sulfonylurea Derivatives of 3,5-Disubstituted Pyrazoles., *J. Pharm. Sci.*, **72**, 999–1004 (1983).
14. Saad, H.A., Osman, N.A., Moustafa, A.H., Synthesis and Analgesic Activity of Some New Pyrazoles and Triazoles Bearing a 6,8-Dibromo-2-methylquinazoline Moiety., *Molecules*, **16**, 10187–10201 (2011).
15. Rathelot, P., Azas, N., El-Kashef, H., Delmas, F., Di Giorgio, C., Timon-David, P., Maldonado, J., Vanelle, P., 1,3-Diphenylpyrazoles: Synthesis and antiparasitic activities of azomethine derivatives., *Eur. J. Med. Chem.*, **37**, 671–9, (2002).
16. Kumari, S., Paliwal, S., Chauhan, R., Synthesis of Pyrazole Derivatives Possessing Anticancer Activity: Current Status., *Synth. Commun.*, **44**, 1521–1578 (2014).
17. Abdellatif, K.R., Design, Synthesis and Anticancer Screening of Novel Pyrazole Derivatives Linking to Benzimidazole, Benzoxazole and Benzothiazole., *Med. Chem. (Los Angeles)*, **S** (2014).
18. Balbi, A., Anzaldi, M., Macciò, C., Aiello, C., Mazzei, M., Gangemi, R., Castagnola, P., Miele, M., Rosano, C., Viale, M., Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity., *Eur. J. Med. Chem.*, **46**, 5293–5309 (2011).
19. Fahmy, H., Khalifa, N., Ismail, M., El-Sahrawy, H., Nossier, E., Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities., *Molecules*, **21**, 271 (2016).

20. Zhang, J.-H., Fan, C.-D., Zhao, B.-X., Shin, D.-S., Dong, W.-L., Xie, Y.-S., Miao, J.-Y., Synthesis and preliminary biological evaluation of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as potential agents against A549 lung cancer cells., *Bioorg. Med. Chem.*, **16**, 10165–10171 (2008).
21. Hafez, H., Microwave-Assisted Synthesis and Cytotoxicity Evaluation of Some Novel Pyrazole Containing Imidazole, Pyrazole, Oxazole, Thiadiazole and Benzochromene derivatives., *Egypt. J. Chem.*, **60**, 5–9 (2017).
22. El-Arab, E.E., Synthesis and Cytotoxicity of Novel Pyrazole Derivatives Derived from 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one., *Egypt. J. Chem.*, **58**, 741–753 (2015).
23. Bouabdallah, I., M'Barek, L.A., Ziad, A., Ramdani, A., Zidane, I., Melhaoui, A., Anticancer effect of three pyrazole derivatives., *Nat. Prod. Res.*, **20**, 1024–1030 (2006).
24. Havrylyuk, D., Zimenkovsky, B., Vasylenko, O., Zaprutko, L., Gzella, A., Lesyk, R., Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity., *Eur. J. Med. Chem.*, **44**, 1396–1404 (2009).
25. Shaharyar, M., Abdullah, M.M., Bakht, M.A., Majeed, J., Pyrazoline bearing benzimidazoles: Search for anticancer agent., *Eur. J. Med. Chem.*, **45**, 114–119 (2010).
26. Islam, F., Hossain, M.A., Shah, N.M., Barua, H.T., Kabir, M.A., Khan, M.J., Mullick, R., Synthesis, Characterization, and Antimicrobial Activity Studies of Ni(II) Complex with Pyridine as a Ligand., *J. Chem.*, **2015**, 1–8 (2015).
27. Moustafa, A.H., El-Sayed, H.A., Haikal, A.E.-F.Z., El-Hady, R.A.A., Synthesis and Antimicrobial Activity of Some 2-Pyridone Nucleosides Containing a Sulfonamide Moiety., *Nucleosides, Nucleotides and Nucleic Acids*, **32**, 221–238 (2013).
28. Ramadan, E.S., Sharshira, E.M., El Sokkary, R.I., Morsy, N., Synthesis and antimicrobial evaluation of some heterocyclic compounds from 3-aryl-1-phenyl-1H-pyrazole-4-carbaldehydes., *Zeitschrift für Naturforsch. B*, **73**, 389–397 (2018).
29. Brahmbhatt D I, Kaneriankit R, Patel Anil K, P.N.H., Synthesis and antimicrobial screening of some 3-[4-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-6-aryl-pyridin-2-yl] and 4-methyl-3-phenyl-6-[4-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-6-aryl-pyridin-2-yl] coumarins., *Indian J. Chem.*, **49B**, 971–977 (2010).
30. Atta-Allah, S.R., Abou-Elmagd, W.S.I., Kandeel, K.A.A., Hemdan, M.M., Haneen, D.S.A., A. Youssef, A.S., Synthesis and antimicrobial activity evaluation of some novel hydrazone, pyrazolone, chromenone, 2-pyridone and 2-pyrone derivatives., *J. Chem. Res.*, **41**, 617–623 (2017).
31. Konkala, V.S., Dubey, P.K., Sulfamic acid as a green, reusable catalyst for stepwise, tandem & one-pot solvent-free synthesis of pyrazole derivatives., *Chinese Chem. Lett.*, **28**, 1571–1576 (2017).
32. Taherkhorsand, H., Nikpassand, M., One-pot Synthesis of Novel 2-pyrazolo-3-phenyl-1,3-thiazolidine-4-ones Using DSDABCOC as an Effective Media., *Comb. Chem. High Throughput Screen.*, **21**, 65–69 (2018).
33. Hansen, M.B., Nielsen, S.E., Berg, K., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill., *J. Immunol. Methods*, **119**, 203–10 (1989).
34. Vilsmeier, A., Haack, A., Über die Einwirkung von Halogenphosphor auf Alkyl-formanilide. Eine neue Methode zur Darstellung sekundärer und tertiärer p-Alkylamino-benzaldehyde., *Berichte der Dtsch. Chem. Gesellschaft (A B Ser.)*, **60**, 119–122 (1927).
35. Kira, M.A., Abdel-Rahman, M.O., Gadalla, K.Z., The vilsmeier-haack reaction - III Cyclization of hydrazones to pyrazoles., *Tetrahedron Lett.*, **10**, 109–110 (1969).
36. Singh, K., Ralhan, S., Sharma, P.K., Dhawan, S.N., Vilsmeier-Haack reaction on hydrazones: a convenient synthesis of 4-formylpyrazoles., *J. Chem. Res.*, **2005**, 316–318 (2005).
37. el-Emary, T.I., Bakhite, E.A., Synthesis and biological screening of new 1,3-diphenylpyrazoles with different heterocyclic moieties at position-4., *Pharmazie*, **54**, 106–11 (1999).
38. Kambe, S., Saito, K., Sakurai, A., Midorikawa, H., A Simple Method for the Preparation of 2-Amino-4-aryl-3-cyanopyridines by the Condensation of Malononitrile with Aromatic Aldehydes and Alkyl Ketones in the Presence of Ammonium Acetate., *Synthesis (Stuttg.)*, **1980**, 366–368 (1980).
39. Azizi, N., Haghayegh, M.S., Greener and Additive-Free Reactions in Deep Eutectic Solvent: One-Pot, Three-Component Synthesis of Highly Substituted Pyridines., *Chemistry Select*, **2**, 8870–8873 (2017).

(Received 28/9/2018;
accepted 29/10/2018)

تحضير وتفاعلات وتقييم النشاط المضاد للأورام السرطانية لبعض مشتقات ١ و٣- ثنائي فينيل بيرازول - ٤ - كربوكس ألددهيد الجديدة

عاطف عامر^١، نيفين رمسيس^١ وسباعي محجوب^٢

^١قسم الكيمياء - كلية العلوم - جامعة الزقازيق - مصر

^٢قسم الأبحاث والتطوير - يونيفارما للأدوية - العبور - مصر.

تأكيداً على اهتمامنا المستمر بتحضير مركبات حلقيّة غير متجانسة ذات النشاط البيولوجي المتوقع، تم في هذه الدراسة تحضير بعض مشتقات البيرازول الجديدة المحتوية على نواة البيريدين من خلال تفاعل «فيلزماير-هاك» والذي يُعد إحدى الطرق الشائعة لتحضير مشتقات 4- فورميل بيرازول. تم إجراء مسح بيولوجي لبعض المركبات الجديدة كمضادات للأورام السرطانية، وأظهرت بعض المركبات نشاطاً ملحوظاً مقارنةً بالأدوية المرجعية. تم إثبات التركيب الكيميائي لجميع المركبات الجديدة عن طريق التحليل العنصري للكربون والهيدروجين والنيتروجين وطيف الأشعة تحت الحمراء وكذلك الرنين النووي المغناطيسي لنواة ذرة الهيدروجين إضافةً إلى تحليل طيف الكتلة لجميع المركبات.